GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
- Conditions
- Crohn's DiseaseUlcerative Colitis
- Interventions
- Drug: UTTR1147A
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT03650413
- Locations
- 🇵🇱
Endoskopia Sp. z o.o., Sopot, Poland
🇵🇱Synexus - Poznan, Poznan, Poland
🇧🇬MHAT Saint Karidad EAD, Plovdiv, Bulgaria
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT03606460
- Locations
- 🇺🇸
Dragonfly Research, LLC, Wellesley, Massachusetts, United States
🇺🇸University of Colorado; Anschutz Medical Campus Department of Neurology, Aurora, Colorado, United States
🇺🇸Cleveland Clinic Fndn, Cleveland, Ohio, United States
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT03563716
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
🇺🇸Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
🇺🇸SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT03558152
- Locations
- 🇵🇱
Synexus Polska Sp. z o.o. Oddzial w Gdansku, Gda?sk, Poland
🇷🇸Clinical Hospital Center Zvezdara, Belgrade, Serbia
🇵🇱Klimed Marek Klimkiewicz, Piotrków Trybunalski, Poland
Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: DHES0815A
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03451162
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT03448042
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, Rhône, France
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸START MADRID_Hospital Universiario Fundacion Jimenez Diaz, Madrid, Spain
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT03407482
- Locations
- 🇺🇸
Shanahan Rheumatology & Immunology, PLLC, Raleigh, North Carolina, United States
🇧🇷Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*, Santo Andre, SP, Brazil
🇺🇸Clinical Research of West Florida, Clearwater, Florida, United States
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03381144
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03361137
- Locations
- 🇺🇸
Childrens Hospital of LA, Los Angeles, California, United States
🇺🇸Indiana Hemophilia & Thrombosis center, Indianapolis, Indiana, United States
🇺🇸Newark Beth Israel Medical Center, Newark, New Jersey, United States
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT03341884
- Locations
- 🇺🇸
American Research Corporation Inc., San Antonio, Texas, United States
🇺🇸Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸New Orleans Center for Clinical Research, Knoxville, Tennessee, United States